Parker Laboratories has led a consortium making an investment in Solstice Pharmaceuticals that's designed to fund the company's development of a new ultrasound contrast agent.
The agent is based on microbubble technology that allows image contrast to be precisely engineered and optimized with custom-made monodisperse microbubbles for use in a wide range of applications. It aims to enhance image contrast, improve diagnostic accuracy, and make ultrasound scanning more widely applicable.
Parker's investment speeds up the clinical development of the contrast agent. The amount of the investment was not disclosed.
